Next Article in Journal
Bioactive Hydantoin Alkaloids from the Red Sea Marine Sponge Hemimycale arabica
Next Article in Special Issue
Structural and Immunological Activity Characterization of a Polysaccharide Isolated from Meretrix meretrix Linnaeus
Previous Article in Journal
Chitosanases from Family 46 of Glycoside Hydrolases: From Proteins to Phenotypes
Previous Article in Special Issue
Salt Effect on the Antioxidant Activity of Red Microalgal Sulfated Polysaccharides in Soy-Bean Formula
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2015, 13(11), 6588-6608; doi:10.3390/md13116588

Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis

1
Inserm U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Groupe Biothérapies et Glycoconjugués, 93000 Bobigny, France
2
Laboratoire de Biochimie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris, 93140 Bondy, France
3
ERL CNRS 9215, CRRET Laboratory, Université Paris Est Créteil, 94010 Créteil, France
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Paola Laurienzo
Received: 29 July 2015 / Revised: 18 September 2015 / Accepted: 19 October 2015 / Published: 28 October 2015
(This article belongs to the Collection Marine Polysaccharides)
View Full-Text   |   Download PDF [1701 KB, uploaded 28 October 2015]   |  

Abstract

Induction of angiogenesis is a potential treatment for chronic ischemia. Low molecular weight fucoidan (LMWF), the sulfated polysaccharide from brown seaweeds, has been shown to promote revascularization in a rat limb ischemia, increasing angiogenesis in vivo. We investigated the potential role of two heparan sulfate (HS) metabolism enzymes, exostosin-2 (EXT2) and heparanase (HPSE), and of two HS-membrane proteoglycans, syndecan-1 and -4 (SDC-1 and SDC-4), in LMWF induced angiogenesis. Our results showed that LMWF increases human vascular endothelial cell (HUVEC) migration and angiogenesis in vitro. We report that the expression and activity of the HS-degrading HPSE was increased after LMWF treatment. The phenotypic tests of LMWF-treated and EXT2- or HPSE-siRNA-transfected cells indicated that EXT2 or HPSE expression significantly affect the proangiogenic potential of LMWF. In addition, LMWF increased SDC-1, but decreased SDC-4 expressions. The effect of LMWF depends on SDC-4 expression. Silencing EXT2 or HPSE leads to an increased expression of SDC-4, providing the evidence that EXT2 and HPSE regulate the SDC-4 expression. Altogether, these data indicate that EXT2, HPSE, and SDC-4 are involved in the proangiogenic effects of LMWF, suggesting that the HS metabolism changes linked to LMWF-induced angiogenesis offer the opportunity for new therapeutic strategies of ischemic diseases. View Full-Text
Keywords: fucoidan; angiogenesis; human endothelial cell; glycosaminoglycan; syndecan; heparanase fucoidan; angiogenesis; human endothelial cell; glycosaminoglycan; syndecan; heparanase
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Haddad, O.; Guyot, E.; Marinval, N.; Chevalier, F.; Maillard, L.; Gadi, L.; Laguillier-Morizot, C.; Oudar, O.; Sutton, A.; Charnaux, N.; Hlawaty, H. Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis. Mar. Drugs 2015, 13, 6588-6608.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top